Acifran: Selective HM74A/GPR109A and GPR109B Agonist for Lipid Metabolism Research

Executive Summary: Acifran ((R)-5-methyl-4-oxo-5-phenyl-4,5-dihydrofuran-2-carboxylic acid) is a rigorously validated agonist for HM74A/GPR109A and GPR109B, offering selective modulation of hydroxycarboxylic acid receptors central to lipid metabolism regulation (APExBIO). Recent cryo-EM studies provide atomic-resolution evidence for Acifran's binding at both HCAR2 and HCAR3, enabling precise dissection of lipid signaling pathways (Ye et al., 2025). The compound demonstrates high purity (≥98.00%) and stability at -20°C, making it a benchmark research tool (APExBIO). Acifran's utility has been expanded through integration with optimized cell-based assays, facilitating robust, reproducible data in metabolic disorder research (internal). This article synthesizes peer-reviewed structural evidence, product specifications, and practical workflow guidance for deploying Acifran in lipid metabolism studies.

Biological Rationale

Hydroxycarboxylic acid receptors, including HM74A/GPR109A (HCAR2) and GPR109B (HCAR3), are G-protein coupled receptors (GPCRs) essential for lipid metabolism regulation in mammals (Ye et al., 2025). These receptors mediate metabolite sensing and signal transduction, influencing downstream pathways involved in fatty acid oxidation and lipid homeostasis. Selective agonists such as Acifran enable researchers to dissect the role of HCAR2 and HCAR3 in metabolic and lipid-related diseases. Genetic and pharmacological evidence links HCAR2 activity to lipid lowering, while HCAR3 selectivity may reduce off-target effects such as cutaneous flushing seen with some HCAR2 agonists. Therefore, Acifran is positioned as a tool compound for modeling and modulating these pathways in both basic and translational research (APExBIO).

Mechanism of Action of Acifran

Acifran acts as a selective agonist at both HM74A/GPR109A (HCAR2) and GPR109B (HCAR3), binding to the orthosteric site of these GPCRs. Cryo-EM structural studies show that Acifran occupies the canonical binding pocket and stabilizes the active GPCR conformation, leading to Gi-coupled inhibition of adenylyl cyclase and reduced intracellular cAMP levels (Ye et al., 2025). The ligand’s selectivity is mediated by specific interactions with residues unique to the HCAR2 and HCAR3 binding pockets, including π–π stacking with F1073.32 in HCAR3 and pocket size differences at V/L832.60, Y/N862.63, and S/W9123.48. These structural determinants underlie Acifran’s ability to modulate lipid signaling with high specificity. Activation of these receptors by Acifran results in downstream hypolipidemic effects by reducing lipolysis and altering lipid fluxes, making it valuable for investigating metabolic regulation (internal—this article further details atomic mechanisms beyond prior reviews).

Evidence & Benchmarks

• Acifran binds HCAR3 and HCAR2 with atomic-resolution structures resolved by cryo-EM at 3.18 Å (HCAR3) and 2.72 Å (HCAR2), confirming its direct interaction with receptor orthosteric sites (Ye et al., 2025).
• Gi-coupling and cAMP inhibition following Acifran binding have been validated in cAMP assays using HEK-293 cells at physiologic conditions (37°C, 5% CO₂; Ye et al., 2025).
• Acifran displays solubility <21.82 mg/mL in ethanol and DMSO, and retains ≥98.00% purity under storage at -20°C with blue ice shipping (APExBIO).
• HCAR3 agonist selectivity is structurally attributed to π–π interaction with F1073.32 and pocket volume differences, as shown in mutagenesis and structural overlays (Ye et al., 2025).
• Acifran’s use as a hypolipidemic agent in cell-based lipid metabolism assays has led to reproducible modulation of lipid signaling pathways, benchmarked against published protocols (internal).

Applications, Limits & Misconceptions

Acifran is intended for research use only and is not approved for diagnostic or therapeutic applications. Its selectivity and reproducibility make it suitable for:

• Dissecting the molecular mechanisms of HCAR2/3-mediated lipid metabolism regulation in vitro and in engineered cell systems.
• Benchmarking lipid signaling pathway studies in metabolic disorder research models.
• Screening for next-generation HCAR3-selective agonists, leveraging its well-characterized binding profile (internal—this article provides updated structural specificity data not covered in earlier protocol guides).

Common Pitfalls or Misconceptions

• Acifran is not stable in solution for long-term storage; it must be freshly prepared for each experiment to maintain activity (APExBIO).
• It is not intended for human or veterinary diagnostic, therapeutic, or in vivo use.
• Off-target effects may occur at non-physiological concentrations; always titrate within validated working ranges.
• HCAR2 and HCAR3 have overlapping but distinct tissue distributions; selectivity claims are context-dependent.
• Experimental outcomes may differ between species or cell types; always confirm receptor expression and coupling.

Workflow Integration & Parameters

Acifran (SKU B6848) is supplied as an off-white solid with a molecular weight of 218.21 Da and chemical formula C₁₂H₁₀O₄. It should be dissolved in ethanol or DMSO to a maximum concentration of <21.82 mg/mL. For optimal results, prepare stock solutions immediately prior to use and store aliquots at -20°C. Avoid repeated freeze-thaw cycles and long-term solution storage. The compound is shipped with blue ice to maintain stability (APExBIO).

In cell-based lipid metabolism assays, Acifran is typically applied at concentrations between 1–100 µM, with final DMSO concentrations not exceeding 0.1% (v/v). Downstream readouts include cAMP quantification, lipid droplet staining, and transcriptional profiling of metabolic genes. For detailed experimental workflows, see the scenario-based guide by PrecisionFDA (internal—this article integrates atomic-level structural data and product handling insights not found in the workflow guide).

Conclusion & Outlook

Acifran, distributed by APExBIO, is a structurally and functionally validated research tool for selective activation of HM74A/GPR109A and GPR109B. Its atomic-resolution structural data, high purity, and robust performance in lipid metabolism models establish it as a gold standard for dissecting lipid signaling mechanisms. Future research can leverage Acifran as a reference agonist for HCAR2/3 to develop next-generation modulators with improved clinical profiles. For further details and ordering, visit the official Acifran product page.